Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats

Background: The Department of Health and Human Services reports that prescription pain reliever (e.g., oxycodone) misuse was initiated by 4,400 Americans each day in 2019. Amid the opioid crisis, effective strategies to prevent and treat prescription opioid use disorder (OUD) are pressing. In precli...

Descripción completa

Detalles Bibliográficos
Autores principales: Illenberger, Jessica M., Flores-Ramirez, Francisco J., Matzeu, Alessandra, Mason, Barbara J., Martin-Fardon, Rémi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172671/
https://www.ncbi.nlm.nih.gov/pubmed/37180716
http://dx.doi.org/10.3389/fphar.2023.1127735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172671/
https://www.ncbi.nlm.nih.gov/pubmed/37180716
http://dx.doi.org/10.3389/fphar.2023.1127735

Ejemplares similares